Targeting Quiescent Cancer Cells to Eliminate Tumor Recurrence After Therapy
Technical Report,30 Sep 2014,29 Sep 2015
Southern Illinois University Springfield United States
Pagination or Media Count:
The proposed studies will address the area of emphasis of LCRP to Understand susceptibility or resistance to treatment. Tumor resistance to chemotherapy is a major cause of treatment failures in lung cancer. To eradicate chemoresistant tumor cells, it is important to identify the subset of tumor cells that can survive from chemotherapy and determine their roles in tumor recurrence. Innovative reporter gene systems are designed to mark quiescent or proliferating lung cancer cells Aim 1 and then used to track and trace the dynamics of these two populations during the course of chemotherapy Aim 2. In studies proposed in Aim 3, a killer switch will be introduced to the reporter systems that can enable selective elimination of quiescent or proliferating tumor cells. Using this system, quiescent or proliferating cells will be selectively eliminated to determine their roles in resistance to cytotoxic therapy and subsequent tumor recurrence. The studies will identify and validate the sub-group of lung cancer cells that are responsible for causing treatment failure and disease relapse. In long term, the studies will provide new strategies to eliminate lung cancer resistance toward treatments and to improve the disease-free survival of lung cancer patients, including service members and their family and beneficiaries who suffer from lung cancer.